Compare PAGS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAGS | BEAM |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | PAGS | BEAM |
|---|---|---|
| Price | $11.42 | $27.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | $11.86 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 4.1M | 2.1M |
| Earning Date | 03-05-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ 16.68 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $3,662,823,389.00 | $55,701,000.00 |
| Revenue This Year | $14.75 | N/A |
| Revenue Next Year | $5.68 | $22.06 |
| P/E Ratio | $8.03 | ★ N/A |
| Revenue Growth | ★ 10.88 | N/A |
| 52 Week Low | $6.70 | $13.53 |
| 52 Week High | $12.32 | $36.44 |
| Indicator | PAGS | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 59.26 | 45.52 |
| Support Level | $10.53 | $24.30 |
| Resistance Level | $11.90 | $29.26 |
| Average True Range (ATR) | 0.51 | 2.13 |
| MACD | -0.04 | -0.64 |
| Stochastic Oscillator | 58.31 | 26.59 |
PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.